A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

680

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Carcinoma
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Carcinoma

Interventions

DRUG: PF-08046054
DRUG: Docetaxel monotherapy

Sponsor

Pfizer